Loading...
•
Sep 30, 2022
Lineage Q3 2022 Earnings Report
Reported third quarter financial results and provided a business update.
Key Takeaways
Lineage Cell Therapeutics reported a net loss attributable to Lineage for the three months ended September 30, 2022, was $6.1 million, or $0.04 per share (basic and diluted), compared to a net loss attributable to Lineage of $7.8 million, or $0.05 per share (basic and diluted), for the same period in 2021. Total revenues for the three months ended September 30, 2022 were approximately $3.0 million, a net increase of $0.7 million as compared to $2.3 million for the same period in 2021.
RG6501 (OpRegen®) has shown potential to slow, stop, or reverse the progression of GA in a phase 1/2a clinical trial.
Focus is turning to planned regulatory interactions for OPC1 and VAC2 to inform and enable their next phases of clinical development.
Advancing newly launched cell transplant programs in photoreceptors for vision disorders and auditory neurons for hearing loss.
Cash, cash equivalents, and marketable securities totaled $66.4 million as of September 30, 2022, which is expected to support planned operations into Q3 2024.
Forward Guidance
Lineage expects that its cash, cash equivalents, and marketable securities will support planned operations into Q3 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...